🔗 Share this article

Given that the US undertakes unprecedented revisions to its vaccine schedules, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about coronavirus shots during the pandemic and has zeroed in on possible fatalities following Covid vaccination in her recent position at the Food and Drug Administration.

Planned Overhauls to Childhood Vaccine Schedule

Health officials were set to unveil radical revisions to the childhood immunization program in December, bringing the US with the Danish immunization schedule, it is understood – a significant shift that would put the US out of alignment with much of the global community with insufficient data for improved outcomes. This reveal has been delayed until the next year.

In place of the director of the vaccine center, Tracy Beth Høeg is set to speak at the gathering. She was just designated interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the center this calendar year.

A Shift at the Regulatory Body

The acting appointment might represent a closer partnership between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a greater focus upon rolling back long-standing vaccines at the FDA.

The new acting director has repeatedly called for halting some pediatric vaccine recommendations in the US to become more similar to the Danish model, a country with nationalized medicine and a citizenry about the population of Wisconsin’s.

To date statements, she has kept her attention on vaccines – usually the purview of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Questions Over Qualifications

Høeg has no obvious experience in pharmaceutical research, regulation or leadership, which has been typical for past heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She appears not to have the requisite experience” for leading the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a clinical trial. She is not versed in leading a major agency. She has no expertise in drug approvals.”

Former heads of CBER would “be deeply familiar with legal statutes and the science of medication creation”, commented a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that prior appointees who ran the center have had.”

CDER has an enormous portfolio at the agency, Woodcock stated.

“The public just focuses on the innovative therapies, but the generic drug division clears a multitude of generic medications. There’s a biologic copycat branch, non-prescription drug unit and other areas, and each of these must be looked after,” Dr. Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a substantial administrative element to the position, which manages over 5,000 personnel. “It is a huge leadership role, if you execute it properly,” the former official said.

Response and Controversial Programs

When asked about questions about Høeg’s qualifications and whether this appointment represents increased cooperation among regulatory chiefs on vaccines, a press secretary responded that the “questions rely on flawed presumptions”.

“Her resume is consistent with the responsibilities of her position,” the spokesperson explained, citing the time Høeg spent advising the agency head on “drug safety and approval science, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the agency head's controversial expedited review system, a disputed one-day therapy clearance system that reportedly troubled her preceding directors. “How are these therapies being chosen for this voucher program? Who is making the calls?” Howard said. “There is a lot of secrecy occurring at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards laxer rules of most medications, except for immunizations.”

Established History on Immunizations

Concerning vaccines, Høeg has a clearer, if troubling, history, Howard have noted. She authored a research paper using unconfirmed public submissions to assess the rate of heart inflammation following COVID-19 immunization. She advised the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccines are more dangerous than they are.

Part of her “policy goals” for the current federal leadership encompassed altering regulations for new vaccines and halting “optional” vaccines, she stated post-election on a online show. At the agency, Dr. Høeg has according to sources proposed preventing adolescent males from getting COVID-19 vaccines.

“She’s an all-around true believer who begins with her preconceived notions and works backwards to accommodate the science in a very misleading, fraudulent fashion,” Howard argued.

Taking Control and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|